Tuesday, November 1, 2016

Tesaro Announces Submission of Niraparib New Drug Application for Platinum-Sensitive, Recurrent Ovarian Cancer

… germline BRCA mutation carriers (non-gBRCAmut), tumor samples were assessed for HRD … niraparib specifically for patients with prostate cancer worldwide, except in Japan. In … . Ovarian cancer is the fifth most frequent cause of cancer death among …

No comments:

Post a Comment